Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
CWG | Ann: Prospectus | 14:33 | 7 | 5.3K | |||
|
|||||||
CWG | Ann: Appendix 5B- Quarterly Cashflow Report | 27/04/15 | 0 | 778 | |||
|
|||||||
CWG | News: Central West Gold granted trading halt | 15/04/15 | 0 | 844 | |||
|
|||||||
CWG | Ann: Suspension from Official Quotation | 15/04/15 | 0 | 883 | |||
|
|||||||
CWG | Ann: Results of General Meeting | 15/04/15 | 0 | 894 | |||
|
|||||||
CWG | Ann: Trading Halt | 15/04/15 | 0 | 850 | |||
|
|||||||
CWG | News: Central West Gold acquiring green technology company | 07/04/15 | 2 | 2.1K | |||
|
|||||||
CWG | Ann: Updated Proxy Form | 20/03/15 | 0 | 578 | |||
|
See All Discussions